(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | ||||||||||||||||||||||||||
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||||||||||||||||||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||||||||||||||||||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||||||||||||||||||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||||||||||||||||||||
Securities registered pursuant to Section 12(b) of the Act: | ||||||||||||||||||||||||||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). |
Exhibit Number | Description | |||||||
16.1 | ||||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
Date: March 17, 2023 | Xeris Biopharma Holdings, Inc. | |||||||||||||
By: | /s/ Steven M. Pieper | |||||||||||||
Name: Steven M. Pieper | ||||||||||||||
Title: Chief Financial Officer |
Cover |
Mar. 13, 2023 |
---|---|
Document Information [Line Items] | |
Document Type | 8-K |
Document Period End Date | Mar. 13, 2023 |
Entity Registrant Name | XERIS BIOPHARMA HOLDINGS, INC. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-40880 |
Entity Tax Identification Number | 87-1082097 |
Entity Address, Address Line One | 180 N. LaSalle Street, |
Entity Address, Address Line Two | Suite 1600 |
Entity Address, City or Town | Chicago |
Entity Address, State or Province | IL |
Entity Address, Postal Zip Code | 60601 |
City Area Code | 844 |
Local Phone Number | 445-5704 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.0001 per share |
Trading Symbol | XERS |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Amendment Flag | false |
Entity Central Index Key | 0001867096 |
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end
F%1G KE ;N35$6#!2EDND\7.'07-@VA#410YN@B-2!0R!_U>
MEW"?\#@BH*M ,L5V7/R\[EVSJ9N6M @Y4:)%U.?
M!4GDC4D$/G#4'\LGTP>"'JR5IO$0V3!UAI+ .* ^_7'6U@?U%]SB RL I]#=HTF<-(>6*;3S ;3EE)1*DWML\@1
M6-Y-L;D2/QC.#6 PE#HYKDY.IA *;*A@+!'%W+/5&4O(GX V961U[H:\!P.:
M-=U4*[D7^:_.H\'&6#?I,BX0
M!CP[: ,]I50ZYH&NAK*V2CMV# BE;FX.X/3!!B>0E3^Q]Y_\&ZL>@I7@;USJ
MYZ9S1,<266DTPB^$-)0ZS56!96GTEAIE#EGVO:":G3-MGO5XLWH;7EH=_$IF
M#\Y4W/-[71G;OK0 KJ]ZG.[Z"9\?'S["?/[X8@RG5[)C78T,Y>CDEEZ\I!U"
M[CR_@BN>/I7[YRLOWI+.GLT=L[[M3O\"4$L#!!0 ( $J!<58*TLKZE1,
M &Z% 1 >&5R
X_WVF_VU%]C:;S699MF9=^5V\?N0S>&*"_'@OI1/Q C&@-)$#)#
M,RS-M/+Y(KYL-H#-+/_YY7/7&;(1U>:AA*DU6/',DQD&[IO=K&I&0ZODV%E8
M["QRL+E'HVS:U6A!RDQ@6S6B69D"3G9O>=0?O"LP7_O:+0"!&76/CT8LI@1'
MT-B/A-^\*[0#/P:VU:['(8#BJ&_O"C&[B\MRYO+Q+[_\
,]<;.[R7\=9U^TLL*_W@=5=)'NHGOX2I
M,C&:E1_*!'BRX;+$::G74[\4F+VU/HD!+\INB+*T'='ST+LYK^+(_!IOM*HD
M9F=('(]&T099 6_82[$GJ#P'Z(Y'O< K1JLS*II/BSNA@/B)47N>9O1*OF39
MI@9R?SOD\,M$.3Q$[']ZQMRE%ZXT]-BT>E)YY"9
06)37U9UW\B/+03<:755MO7-:>4A]JA3%O()1+3'
MB$MBD(D8(^&XS$207#(W NOOBI@,^O%,!PB_O
M-5Y\N<[2QV85$1(B( 8\C#D(A-2 !T( (16.J5)&]]:MYL^#3TWF%3ZO MB[
M6:5!W&$]#Z'CQ#+NP40OX7:E[*371K#19-J5QJXZ.\